Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Inclusion Criteria: - For Japan only: Male or female, age above or equal to 20 years at thetime of signing inform consent - Subjects diagnosed with type 2 diabetes and treated withdiet and exercise for at least 30 days before screening - HbA1c 7.0 - 10.0 % (53 - 86

mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding orintends to become pregnant or is of child-bearing potential and not using adequatecontraceptive method (adequate contraceptive measures as required by local regulation orpractice) throughout the trial including the 5 week follow-up period. United Kingdom:Adequate contraceptive measures are defined as established use of oral, injected orimplanted hormonal methods of contraception, placement of an intrauterine device orintrauterine system, barrier methods of contraception (condom or occlusive cap withspermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is solepartner of subject), or true abstinence (when in line with preferred and usual lifestyle) -Any chronic disorder or severe disease which, in the opinion of the investigator, mightjeopardise subject's safety or compliance with the protocol - Treatment with any glucoselowering agent(s) in a period of 90 days prior to screening. An exception is short-termtreatment (no longer than 7 days in total) with insulin in connection with inter-currentillness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin valueabove or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroidcarcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal functiondefined as eGFR (estimated glomerular filtration rate ) below 30 mL/min/1.73 m^2 permodification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronaryor cerebrovascular event within 90 days before randomisation - Heart failure, New YorkHeart Association class IV